分享好友 资讯首页 频道列表

FDA Grants Priority Review for Zoliflodacin New Drug Application for the Treatment of Uncomplicated Gonorrhea and Assigns Target PDUFA Date of December 15, 2025

2025-06-16 09:1212410

FDA is expected to notify Innoviva Specialty Therapeutics regarding its decision to conduct an Advisory Committee Meeting in the Day 74 letter

If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades

WALTHAM, Mass. & GENEVA--(BUSINESS WIRE)--Innoviva Specialty Therapeutics, Inc., a subsidiary of Innoviva, Inc. (NASDAQ: INVA), in collaboration with the Global Antibiotic Research & Development Partnership (GARDP), today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review for the New Drug Application (NDA) for zoliflodacin, an investigational first-in-class, single dose, spiropyrimidinetrione oral antibiotic for the treatment of uncomplicated gonorrhea in adults and pediatric patients 12 years and older. The FDA assigned a target action date of December 15, 2025 under the Prescription Drug User-Fee Act (PDUFA). It is expected the FDA will notify Innoviva Specialty Therapeutics regarding the FDA’s decision to conduct an Advisory Committee Meeting in the Day 74 letter. If approved, zoliflodacin would be the first new antibiotic for treating gonorrhea in decades.

The U.S. FDA has granted zoliflodacin a Qualified Infectious Disease Product (QIDP) designation. This designation allows it to benefit from FDA Priority Review, and Extended Market Exclusivity.

Entasis Therapeutics, Inc., the legal NDA holder and affiliate of Innoviva Specialty Therapeutics, Inc., retains the commercial rights for zoliflodacin in the major markets in North America, Europe, and Asia-Pacific. GARDP retains the right to register and commercialize the product in more than three-quarters of the world’s countries, including all low-income countries, most middle-income countries, and several high-income countries. GARDP is committed to working with its partners and local health authorities in markets where zoliflodacin receives regulatory approval to help remove access barriers to ensure treatment is available to address unmet medical needs while ensuring appropriate and sustainable use.

About Uncomplicated Gonorrhea

With more than 82 million new gonorrhea infections occurring globally each year, gonorrhea is the second most common bacterial sexually transmitted infection (STI), affecting both men and women, which, if left untreated, can result in serious and permanent health consequences.

With the rise and spread of drug-resistant infections, the World Health Organization (WHO) has identified antimicrobial resistance (AMR) as one of the ten most critical global threats to public health. The bacterium Neisseria gonorrhoeae, which causes gonorrhea, has progressively developed resistance to most classes of antibiotics used to treat these infections, including ceftriaxone, a widely used intramuscular injection that was first made available in 1984.

About Zoliflodacin

Zoliflodacin is an investigational first-in-class antibacterial that is administered in a single oral dose for the treatment of uncomplicated gonorrhea. The oral route of administration simplifies treatment by providing a convenient option for patients unable to receive an intramuscular injection. Zoliflodacin has a unique mechanism of action, inhibiting a crucial bacterial enzyme called type II topoisomerase, which is essential for bacterial function and reproduction. In in vitro studies, zoliflodacin demonstrated activity against multidrug-resistant strains of Neisseria gonorrhoeae, including those resistant to ceftriaxone and azithromycin, with no cross-resistance to other antibiotics. In a pivotal Phase 3 clinical trial, zoliflodacin demonstrated non-inferiority in achieving microbiological cure at the urogenital site of infection with a single oral dose of zoliflodacin compared to a treatment regimen of a single intramuscular injection of 500mg ceftriaxone followed by 1g of oral azithromycin. The Phase 3 study found that zoliflodacin was generally well-tolerated, with no serious adverse events or deaths reported during the trial.

About GARDP

The Global Antibiotic Research & Development Partnership (GARDP) is a not-for-profit global health organization driven to protect people from the rise and spread of drug-resistant infections, one of the biggest threats to us all. By forging the public and private partnerships that matter, we develop and make accessible antibiotic treatments for people who need them. Vital support for our work comes from the governments of Canada, Germany, Japan, Monaco, the Netherlands, Switzerland, the United Kingdom, the Canton of Geneva, the European Union, as well as the Gates Foundation, Global Health EDCTP3, GSK, the RIGHT Foundation, the South African Medical Research Council (SAMRC) and Wellcome.

About Innoviva

Innoviva is a diversified holding company with a core royalties portfolio, a leading critical care and infectious disease platform known as Innoviva Specialty Therapeutics (“IST”), and a portfolio of strategic investments in healthcare assets. Innoviva’s royalty portfolio includes respiratory assets partnered with Glaxo Group Limited (“GSK”). Innoviva is entitled to receive royalties from GSK on sales of RELVAR®/BREO® ELLIPTA® and ANORO® ELLIPTA®. Innoviva’s other innovative healthcare assets include infectious disease and critical care assets stemming from acquisitions of Entasis Therapeutics, including XACDURO® (sulbactam for injection; durlobactam for injection), co-packaged for intravenous use approved for the treatment of adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia caused by susceptible strains of Acinetobacter baumannii-calcoaceticus complex and the investigational zoliflodacin currently being developed for the treatment of uncomplicated gonorrhea, and La Jolla Pharmaceutical Company, including GIAPREZA® (angiotensin II), approved to increase blood pressure in adults with septic or other distributive shock and XERAVA® (eravacycline) for the treatment of complicated intra-abdominal infections in adults. Innoviva also markets ZEVTERA® (ceftobiprole), an advanced-generation cephalosporin antibiotic, in the U.S. through an exclusive license from Basilea Pharmaceutica International Ltd, Allschwil. For more information about Innoviva, go to www.innoviva.com. For information about Innoviva Specialty Therapeutics, go to www.innovivaSpecialtytherapeutics.com.

ANORO®, RELVAR® and BREO® are trademarks of the GSK group of companies. ZEVTERA® is a trademark of Basilea Pharmaceutica Ltd, Allschwil.

 

Contacts

Media
Innoviva Specialty Therapeutics
David Patti
David.patti@inva.com
+1.908.421.5971

GARDP
Duncan Graham-Rowe
dgrahamrowe@gardp.org
+44 7966 413623

Investors
Argot Partners
innoviva@argotpartners.com
+1.212.600.1902

反对 0
举报 0
收藏 0
打赏 0
评论 0
KIOXIA AiSAQ软件推出新版本向量搜索库,推动AI检索增强生成技术发展
全新开源软件支持根据用户需求与环境灵活平衡容量和性能 东京--(美国商业资讯)--为持续优化固态硬盘(SSD)的使用,提升检索增强生成(RAG)系统中AI向量数据库搜索的可用性,全球存储解决方案领导者Kioxia Corporation今日宣布更新其KIOXIA AiSAQ™(全存储型乘积量化近似最近邻搜索)软件。此次新开源版本引入了灵活控制功能,使系统架构师能够在搜索性能与向量数量之间定义平衡点——这两个因素在系统SSD存储的固定容量中相互制约。这一成果带...

0评论2025-07-071118

诺为泰荣获Frost & Sullivan“2025年全球生物技术CRO公司奖”
澳大利亚悉尼--(美国商业资讯)--凭借卓越的创新能力、客户服务以及国际影响力,Novotech(诺为泰)荣获弗若斯特沙利文 (Frost & Sullivan,简称“沙利文”) 颁发的“2025年全球生物技术CRO公司奖”( 2025 Global Biotechnology Contract Research Organization (CRO) Company of the Year)。 本新闻稿包含多媒体。此处查看新闻稿全文...

0评论2025-07-071259

Pickering Interfaces推出全新高速PXI旋转变压器仿真模块
精准赋能航空航天与汽车行业伺服系统测试全新PXI与PXIe仿真模块支持高达130,000转/分钟的旋转速度,满足新一代伺服系统测试需求 英国克拉克顿海滨--(美国商业资讯)--模块化信号切换与仿真解决方案全球领先供应商 Pickering Interfaces 今日宣布,旗下广受欢迎的PXI(41-670)与PXIe(43-670)系列LVDT、RVDT及旋转变压器仿真模块现已全面升级,支持高达130,000转/分钟的高速旋转变压器仿真,旨在满足航空航天、汽车及国防等关键行业对高性能伺服系统测...

0评论2025-07-071059

ISDA和Ant International牵头撰写关于“守护者计划”下代币化银行负债用于外汇结算和跨境支付的新行业报告
该报告基于共享账本技术以及共同牵头方和“守护者计划”外汇工作组成员的行业专业知识编写而成 报告包含了关于利用代币化银行负债和共享账本的建议原则,以推动行业对代币化的采用,实现全天候实时外汇结算,并为全球企业降低成本 新加坡--(美国商业资讯)--国际互换与衍生品协会(ISDA)和Ant International牵头“守护者计划”(Project Guardian)外汇行业小组,撰写了一份关于在跨境支付和外汇结算中实施代币化银行负债和共享账本的新报告。 本新闻...

0评论2025-07-071050

Venture Global宣布与PETRONAS签署20年购销协议
弗吉尼亚州阿灵顿--(美国商业资讯)-- Venture Global, Inc. (NYSE: VG)今日宣布,与马来西亚国有石油天然气公司PETRONAS的子公司PETRONAS LNG Ltd. (PLL)签署一份新的20年期购销协议(SPA)。根据协议条款,PETRONAS将在20年内每年从Venture Global的第三个设施CP2 LNG每年采购100万吨液化天然气(LNG)。这是对Venture Global与PETRONAS关于每年从Plaquemines LNG设施采购1...

0评论2025-07-071418

穩定幣需求激增,AMINA 銀行宣佈成為全球首家支援 Ripple USD (RLUSD) 的金融機構
受瑞士法規監管的 AMINA 銀行將擴大穩定幣服務,率先提供 RLUSD 的託管與交易 瑞士楚格--(美國商業資訊)-- AMINA Bank AG(以下簡稱「AMINA 銀行」)是一間受瑞士金融市場監管局 (FINMA) 監管,業務遍及全球的加密貨幣銀行。銀行今日宣佈,成為全球首家直接支援 Ripple USD (RLUSD) 的銀行。RLUSD 是一款與美元 1:1 掛鉤的穩定幣,結合了穩定性、高效率與合規優勢。服務上線初期,AMINA 的客戶即可使用 RLUSD 的託管與交易服務,為未來...

0评论2025-07-071348

2025-2026年世界品牌大奖(动物类)表彰全球顶尖宠物与动物品牌
伦敦--(美国商业资讯)-- 2025-2026年世界品牌大奖(World Branding Awards)动物类别奖(Animalis Edition)迎来第五届盛会,汇聚全球顶尖宠物与动物品牌。这些品牌因其杰出成就而备受赞誉,被评为国家、地区和全球优胜品牌。 颁奖盛典在维也纳著名的霍夫堡宫隆重举行,来自宠物食品、零售、健康护理、宠物展会及水族用品等多元领域的获奖品牌齐聚一堂。当晚活动由Mounia Berrada-Gouzi女士优雅主持,最终以一场致敬品牌卓越成就的恢弘庆典圆满落幕。...

0评论2025-07-071174

芯原推出经市场验证的ZSP5000视觉核心系列,扩展其面向边缘智能的数字信号处理器IP组合
具备可扩展的架构和指令集,赋能计算机视觉和图像应用 中国上海--(美国商业资讯)--芯原股份(芯原,股票代码:688521.SH)今日正式发布ZSP5000系列IP。该产品线基于公司第五代经硅验证的数字信号处理器(DSP)架构,采用高可扩展性和低功耗的设计,并针对计算机视觉、嵌入式人工智能等计算密集型应用进行了深度优化,结合架构的可配置能力,该系列IP可为各类边缘设备提供兼具能效优势和计算效率的优秀解决方案。 ZSP5000系列包含ZSP5000、ZSP5000UL、ZSP5000L及ZS...

0评论2025-07-071161

LambdaTest宣布与Appium深化战略合作
此举将通过LambdaTest庞大的真实设备云加速规模化移动测试自动化,实现无与伦比的准确性、速度与全球覆盖。 旧金山--(美国商业资讯)--统一的智能AI与云工程平台LambdaTest近日宣布,其已成为全球应用最广泛的移动自动化开源框架Appium的战略赞助商。此次合作旨在通过将Appium的功能集成到LambdaTest基于云的分布式测试平台中,来大幅简化并加速移动测试自动化流程。 LambdaTest拥有活跃的开源计划,为社区项目提供访问LambdaTest测试基础设施的权限,使维...

0评论2025-07-041152

SE Labs 奖项力证 NetApp 全球最安全存储的卓越地位
NetApp 荣膺 2025 年度 SE Labs 企业数据保护奖 美国加州圣何塞--(美国商业资讯)--智能数据基础设施公司 NetApp® (NASDAQ: NTAP) 今日宣布,公司凭借在网络安全领域的卓越表现,在 SE LABS® 2025 年度评选中备受赞誉。NetApp 荣获 2025 年度 SE Labs 企业数据保护奖,再次印证了其作为全球最安全存储提供商的领先地位。 此次获奖得益于 NetApp 在网络韧性领域的卓越创新。公司推出的集成了人工智能技术的 N...

0评论2025-07-041757